Mitochondrial reactive oxygen species (ROS) cause Ca2+ release from the Endoplasmic reticulum (ER) via ryanodine receptors (RyRs) in pulmonary artery smooth muscle cells (PASMCs), playing an essential role in hypoxic pulmonary vasoconstriction (HPV). Here we tested a novel hypothesis that hypoxia-induced RyR-mediated Ca2+ release may, in turn, promote mitochondrial ROS generation contributing to hypoxic cellular responses in PASMCs. Our data reveal that application of caffeine to elevate intracellular Ca2+ concentration ([Ca2+]i) by activating RyRs results in a significant increase in ROS production in cytosol and mitochondria of PASMCs. Norepinephrine to increase [Ca2+]i due to the opening of inositol 1,4,5-triphosphate receptors (IP3Rs) produces similar effects. Exogenous Ca2+ significantly increases mitochondrial-derived ROS generation as well. Ru360 also inhibits the hypoxic ROS production. The RyR antagonist tetracaine or RyR2 gene knockout (KO) suppresses hypoxia-induced responses as well. Inhibition of mitochondrial Ca2+ uptake with Ru360 eliminates N- and Ca2+-induced responses. RISP KD abolishes the hypoxia-induced ROS production in mitochondria of PASMCs. Rieske iron-sulfur protein (RISP) gene knockdown (KD) blocks caffeine- or NE-induced ROS production. Taken together, these findings have further demonstrated that ER Ca2+ release causes mitochondrial Ca2+ uptake and RISP-mediated ROS production; this novel local ER/mitochondrion communication-elicited, Ca2+-mediated, RISP-dependent ROS production may play a significant role in hypoxic cellular responses in PASMCs.
E20004 Background: Increasing evidence illustrates that exosomal microRNAs in circulating fluids provide a promising way as biomarkers for noninvasive cancer diagnosis. The aim of this study was to evaluate the feasibility of exosomal miRNAs as a diagnostic and prognostic biomarkers in non-small-cell lung cancer (NSCLC). Methods: Blood samples from 40 NSCLC patients and 24 healthy volunteers were collected and matched with age, gender and blood collection time. Plasma exosomes were accessed by 110,000×g ultracentrifugation and visualized by NS300 equipment. The raw data of exosomal miRNA profiles of NSCLC patients and healthy individuals were generated by NGS around 400× read depth and its expression were measured by Taqman probe quantitive PCR. . Results: Exosome numbers were robust in differentiating NSCLC patients from controls [area under the curve (AUC) = 0.800; 95% confidence interval (CI) = 0.685–0.915 P < 0.01]. RNA sequencing data showed 31 miRNAs were up-regulated and 55 miRNAs down-regulated in plasma of NSCLC. TaqMan quantitative RT-PCR analyses indicated that miR-99a, miR-124 and miR-214 were significantly lower in NSCLC patients than in controls. However, miR-21 and miR-126 had significantly higher expression in NSCLC patients. Mir-214 showed high accuracy in discriminating NSCLC patients from healthy controls with a sensitivity of 0.70 and specify of 0.92 (AUC = 0.858, 95% CI = 0.765–0.950 P < 0.001). Furthermore, decreased miR-99a expression was positively correlated with TNM stage (P = 0.007), lymph node metastasis (P = 0.012), and distant metastasis (P < 0.001). Increased miR-21 expression was significantly associated with poorer pathological differentiation (P = 0.015), tumor size (P = 0.033), and lymph node metastasis (P = 0.028). Kaplan–Meier analysis demonstrated that decreased miR-99a expression contributed to poor progression-free survival (PFS) (P < 0.01) of patients. Multivariate analysis indicated that miR-99a was a independent prognostic marker of survival. Conclusions: Exosomal miRNAs in plasma could indicate the progress of NSCLC and a combination of the explored miRNA could serve as a promising biomarker for NSCLS diagnosis and prognosis.
Objectives: This study was conducted to uncover the underlying cellular and molecular mechanisms of five prime to Xist (FTX) dysregulation in esophageal cancer (EC). Methods: The gene expression in tumor tissues was detected using western blot, immunohistochemistry, and quantitative real-time polymerase chain reaction (qPCR). The dual-luciferase reporter and RNA FISH assays confirmed the interaction between miRNA and target genes. Mouse models for Xenograft and lung metastasis were used to assess EC cell tumorigenesis and metastasis. Results: This study finds that up-regulated FTX in patients with esophageal cancer correlates with poor clinical outcomes. Silencing FTX inhibits esophageal cancer cell growth and migration in vitro and tumor metastasis in vivo. miR-99a/b-3p sensitizes esophageal cancer cells to ionizing radiation by WEE1 (Wee1-like protein kinase) and ERCC1 (excision repair cross-complementation group 1) in vitro. Conclusions: FTX promotes the malignant biological phenotype of esophageal cancer cells. Mechanistically, FTX acts as a ceRNA to regulate the transcription of WEE1 and ERCC1 by sponging hsa-miR-99a/b-3p.
25 December 2025 in Journal for ImmunoTherapy of Cancer
Background: The CpG/α-OX40 in situ vaccine strategy has shown efficacy in immune-hot tumors but remains ineffective in immune-cold tumors possibly due to immunosuppressive microenvironments characterized by myeloid-derived suppressor cells (MDSCs) infiltration and T cell exclusion. This study aims to investigate the antitumor effect of non-α-biased IL-2 combined with CpG/α-OX40 in mice. Methods: Using 4T1 breast cancer and CT26 colon cancer models, we evaluated the antitumor effects of combining CpG/α-OX40 with a non-α-biased IL-2 variant via both intratumoral and subcutaneous routes. Tumor growth, lung metastasis, immune profile, and in vitro function analysis were assessed through flow cytometry, transcriptomic analysis, and T cell suppression assays. Results: The combination therapy significantly inhibited primary and distant tumor growth and reduced lung metastasis in 4T1 models. Subcutaneous administration induced complete tumor regression in 55% (5/9) of CT26-tumor-bearing mice and conferred durable tumor-specific memory. Mechanistically, the treatment enhanced CD8 + T cell activation, metabolic reprogramming, and IFN-γ production, while suppressing MDSC expansion and immunosuppressive function. Conclusions: These findings demonstrate that non-α-biased IL-2 synergizes with CpG/α-OX40 to overcome microenvironmental immunosuppression and achieve systemic antitumor immunity via a subcutaneous route, offering a translatable combinatorial strategy for immune-cold tumors.
Purpose This study aimed to investigate the molecular links and mechanisms between Crohn’s disease (CD) and colorectal cancer (CRC). Methods This study used the Gene Expression Omnibus (GEO) database to identify Differentially expressed genes (DEGs) in CD (GSE112366) and CRC (GSE110224), analyzed by 'edgeR' and 'limma'. The Gene Ontology and the Kyoto Encyclopedia of Genes and Genomes explored DEG functions, and the Search Tool for the Retrieval of Interacting Genes (STRING) informed the protein–protein interaction network construction visualized in Cytoscape (version 3.7.2). Cyto-Hubba identified key genes, whose biomarker potential for CD and CRC was evaluated. Results The study discovered 61 DEGs, with 44 up- and 17 down-regulated, linked to immune responses and signaling pathways. CXCL1, highly expressed in colon cancer, correlated with better prognosis and lower staging. It also showed associations with immune infiltration and checkpoint molecules, suggesting a role in cancer progression and retreat. Conclusion CXCL1 may play a role in the development of colorectal cancer from inflammatory bowel disease.
Withdrawal Statement: This manuscript has been withdrawn by the authors as they did not obtain patient consent for the tissue samples use in this study and were, therefore, not able to be approved by the Institute’s Ethics Committee of Wenzhou Medical University. The authors also declare that there are interest conflict about authorship. Therefore, the authors do not wish this work to be cited as reference for the project. If you have any questions, please contact the corresponding author.